Inflammatory biomarkers in patients in Simvastatin treatment: No effect of co-enzyme Q10 supplementation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Inflammatory biomarkers in patients in Simvastatin treatment : No effect of co-enzyme Q10 supplementation. / Hansen, Maria; Kuhlman, Anja C.B.; Sahl, Ronni E.; Kelly, Bo; Morville, Thomas; Dohlmann, Tine L.; Chrøis, Karoline M.; Larsen, Steen; Helge, Jørn W.; Dela, Flemming.

I: Cytokine, Bind 113, 2019, s. 393-399.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Hansen, M, Kuhlman, ACB, Sahl, RE, Kelly, B, Morville, T, Dohlmann, TL, Chrøis, KM, Larsen, S, Helge, JW & Dela, F 2019, 'Inflammatory biomarkers in patients in Simvastatin treatment: No effect of co-enzyme Q10 supplementation', Cytokine, bind 113, s. 393-399. https://doi.org/10.1016/j.cyto.2018.10.011

APA

Hansen, M., Kuhlman, A. C. B., Sahl, R. E., Kelly, B., Morville, T., Dohlmann, T. L., ... Dela, F. (2019). Inflammatory biomarkers in patients in Simvastatin treatment: No effect of co-enzyme Q10 supplementation. Cytokine, 113, 393-399. https://doi.org/10.1016/j.cyto.2018.10.011

Vancouver

Hansen M, Kuhlman ACB, Sahl RE, Kelly B, Morville T, Dohlmann TL o.a. Inflammatory biomarkers in patients in Simvastatin treatment: No effect of co-enzyme Q10 supplementation. Cytokine. 2019;113:393-399. https://doi.org/10.1016/j.cyto.2018.10.011

Author

Hansen, Maria ; Kuhlman, Anja C.B. ; Sahl, Ronni E. ; Kelly, Bo ; Morville, Thomas ; Dohlmann, Tine L. ; Chrøis, Karoline M. ; Larsen, Steen ; Helge, Jørn W. ; Dela, Flemming. / Inflammatory biomarkers in patients in Simvastatin treatment : No effect of co-enzyme Q10 supplementation. I: Cytokine. 2019 ; Bind 113. s. 393-399.

Bibtex

@article{dfd905a2c56943828140d58baff49af9,
title = "Inflammatory biomarkers in patients in Simvastatin treatment: No effect of co-enzyme Q10 supplementation",
abstract = "Purpose: Atherosclerosis is a major risk factor for cardiovascular disease (CVD) and is known to be an inflammatory process. Statin therapy decreases both cholesterol and inflammation and is used in primary and secondary prevention of CVD. However, a statin induced decrease of plasma concentrations of the antioxidant coenzyme Q10 (CoQ10), may prevent the patients from reaching their optimal anti-inflammatory potential. Here, we studied the anti-inflammatory effect of Simvastatin therapy and CoQ10 supplementation. Methods: 35 patients in primary prevention with Simvastatin (40 mg/day) were randomized to receive oral CoQ10 supplementation (400 mg/d) or placebo for 8 weeks. 20 patients with hypercholesterolemia who received no cholesterol-lowering treatment was a control group. Plasma concentrations of lipids and inflammatory biomarkers (interleukin-6 (IL6); -8 (IL8); -10 (IL10), tumor necrosis factor-α (TNFα); high-sensitivity C reactive protein (hsCRP)) as well as glycated hemoglobin (HbA1c) were quantified before and after the intervention. Results: No significant change in inflammatory markers or lipids was observed after CoQ10 supplementation Patients in Simvastatin therapy had significantly (P < 0.05) lower baseline concentration of IL6 (0.31 ± 0.03 pg/ml), IL8 (1.6 ± 0.1 pg/ml) IL10 (0.16 ± 0.02 pg/ml) and borderline (P = 0.053) lower TNFα (0.88 ± 0.05 pg/ml), but not hsCRP (1.34 ± 0.19 mg/l) compared with the control group (0.62 ± 0.08, 2.6 ± 0.2, 0.25 ± 0.01, 1.07 ± 0.09, and 1.90 ± 0.35, respectively). Conclusions: Simvastatin therapy has beneficial effects on inflammatory markers in plasma, but CoQ10 supplementation seems to have no additional potentiating effect in patients in primary prevention. In contrast, glucose homeostasis may improve with CoQ10 supplementation.",
keywords = "Antioxidant, Dyslipidemia, Hemoglobin A1C, Inflammation",
author = "Maria Hansen and Kuhlman, {Anja C.B.} and Sahl, {Ronni E.} and Bo Kelly and Thomas Morville and Dohlmann, {Tine L.} and Chr{\o}is, {Karoline M.} and Steen Larsen and Helge, {J{\o}rn W.} and Flemming Dela",
year = "2019",
doi = "10.1016/j.cyto.2018.10.011",
language = "English",
volume = "113",
pages = "393--399",
journal = "Cytokine",
issn = "1043-4666",
publisher = "Academic Press",

}

RIS

TY - JOUR

T1 - Inflammatory biomarkers in patients in Simvastatin treatment

T2 - No effect of co-enzyme Q10 supplementation

AU - Hansen, Maria

AU - Kuhlman, Anja C.B.

AU - Sahl, Ronni E.

AU - Kelly, Bo

AU - Morville, Thomas

AU - Dohlmann, Tine L.

AU - Chrøis, Karoline M.

AU - Larsen, Steen

AU - Helge, Jørn W.

AU - Dela, Flemming

PY - 2019

Y1 - 2019

N2 - Purpose: Atherosclerosis is a major risk factor for cardiovascular disease (CVD) and is known to be an inflammatory process. Statin therapy decreases both cholesterol and inflammation and is used in primary and secondary prevention of CVD. However, a statin induced decrease of plasma concentrations of the antioxidant coenzyme Q10 (CoQ10), may prevent the patients from reaching their optimal anti-inflammatory potential. Here, we studied the anti-inflammatory effect of Simvastatin therapy and CoQ10 supplementation. Methods: 35 patients in primary prevention with Simvastatin (40 mg/day) were randomized to receive oral CoQ10 supplementation (400 mg/d) or placebo for 8 weeks. 20 patients with hypercholesterolemia who received no cholesterol-lowering treatment was a control group. Plasma concentrations of lipids and inflammatory biomarkers (interleukin-6 (IL6); -8 (IL8); -10 (IL10), tumor necrosis factor-α (TNFα); high-sensitivity C reactive protein (hsCRP)) as well as glycated hemoglobin (HbA1c) were quantified before and after the intervention. Results: No significant change in inflammatory markers or lipids was observed after CoQ10 supplementation Patients in Simvastatin therapy had significantly (P < 0.05) lower baseline concentration of IL6 (0.31 ± 0.03 pg/ml), IL8 (1.6 ± 0.1 pg/ml) IL10 (0.16 ± 0.02 pg/ml) and borderline (P = 0.053) lower TNFα (0.88 ± 0.05 pg/ml), but not hsCRP (1.34 ± 0.19 mg/l) compared with the control group (0.62 ± 0.08, 2.6 ± 0.2, 0.25 ± 0.01, 1.07 ± 0.09, and 1.90 ± 0.35, respectively). Conclusions: Simvastatin therapy has beneficial effects on inflammatory markers in plasma, but CoQ10 supplementation seems to have no additional potentiating effect in patients in primary prevention. In contrast, glucose homeostasis may improve with CoQ10 supplementation.

AB - Purpose: Atherosclerosis is a major risk factor for cardiovascular disease (CVD) and is known to be an inflammatory process. Statin therapy decreases both cholesterol and inflammation and is used in primary and secondary prevention of CVD. However, a statin induced decrease of plasma concentrations of the antioxidant coenzyme Q10 (CoQ10), may prevent the patients from reaching their optimal anti-inflammatory potential. Here, we studied the anti-inflammatory effect of Simvastatin therapy and CoQ10 supplementation. Methods: 35 patients in primary prevention with Simvastatin (40 mg/day) were randomized to receive oral CoQ10 supplementation (400 mg/d) or placebo for 8 weeks. 20 patients with hypercholesterolemia who received no cholesterol-lowering treatment was a control group. Plasma concentrations of lipids and inflammatory biomarkers (interleukin-6 (IL6); -8 (IL8); -10 (IL10), tumor necrosis factor-α (TNFα); high-sensitivity C reactive protein (hsCRP)) as well as glycated hemoglobin (HbA1c) were quantified before and after the intervention. Results: No significant change in inflammatory markers or lipids was observed after CoQ10 supplementation Patients in Simvastatin therapy had significantly (P < 0.05) lower baseline concentration of IL6 (0.31 ± 0.03 pg/ml), IL8 (1.6 ± 0.1 pg/ml) IL10 (0.16 ± 0.02 pg/ml) and borderline (P = 0.053) lower TNFα (0.88 ± 0.05 pg/ml), but not hsCRP (1.34 ± 0.19 mg/l) compared with the control group (0.62 ± 0.08, 2.6 ± 0.2, 0.25 ± 0.01, 1.07 ± 0.09, and 1.90 ± 0.35, respectively). Conclusions: Simvastatin therapy has beneficial effects on inflammatory markers in plasma, but CoQ10 supplementation seems to have no additional potentiating effect in patients in primary prevention. In contrast, glucose homeostasis may improve with CoQ10 supplementation.

KW - Antioxidant

KW - Dyslipidemia

KW - Hemoglobin A1C

KW - Inflammation

U2 - 10.1016/j.cyto.2018.10.011

DO - 10.1016/j.cyto.2018.10.011

M3 - Journal article

VL - 113

SP - 393

EP - 399

JO - Cytokine

JF - Cytokine

SN - 1043-4666

ER -

ID: 214948850